OKYO Pharma Ltd ADR (OKYO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.36 (+3.03%), Market cap $0.09B, 52-week low–high $1.34 ~ $3.27.
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Financial statements, price targets, institutional (13F) holdings and related news for OKYO Pharma Ltd ADR are updated in real time on BlackAll Trade.
OKYO Pharma Ltd ADR trades at $1.36 (+3.03%). Real-time quotes and charts are available on BlackAll Trade.
OKYO Pharma Ltd ADR has a market cap of about $0.09B.
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical pr